Skip to main content

ChanTest, FDA Partner on Cardiac Safety Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ChanTest is collaborating with the US Food and Drug Administration to develop assays to improve prediction of cardiac safety, the company announced on Thursday.

Under the deal with the FDA's Center for Drug Evaluation and Research, the Cleveland-based firm will develop non-clinical assays, databases, and computational models for assessing the risk of serious cardiac events associated with drug-induced QT prolongation. Research will also be done to identify gaps in current safety testing methods for new drugs.

Terms of the deal were not disclosed.

In a statement, ChanTest said that the hERG assay, a primary method of classifying investigational drugs with the potential to prolong the QT interval, is generally viewed as being insufficiently sensitive and specific to predict the clinical risk of QT prolongation and serious ventricular arrhythmia accurately across all chemical and drug classes. While seeking to identify gaps in current safety testing, the collaboration will improve understanding of the cellular basis for serious clinical events associated with QT prolongation, it said.

ChanTest offers ion channel and GPCR screening services to research and drug discovery and development customers.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.